Appropriate histopathological, immunohistochemical, and sometimes genetic testing are required for correct diagnosis of ALK-negative IMT.[18] Recent advances have revealed that ALK-negative IMTs harbor ALK gene rearrangements related to other multiple potentially actionable kinase fusions, such as RET, ROS1, ETV6, NTRK1, NTRK2, NTRK3, and PDGFRB,[19–21] giving rise to genome-level research into potential carcinogenic process. Here, ROS1 is linked to inflammatory myofibroblastic tumor.